Arcus Biosciences, Inc. (RCUS) Form 8-K — Nov 4, 2026
Arcus Biosciences (NYSE: RCUS) reported Q3 2026 financial results, with revenues of $9 million (down from $26 million a year ago) and a net loss of $128 million, or $1.00 per share. The pipeline story dominated: October ARC-20 data showed casdatifan delivering 35-month median overall survival in late-line kidney cancer and 14.5-month median PFS in second-line ccRCC with cabozantinib, exceeding third-party benchmarks. PEAK-1 Phase 3 enrollment is expected to complete within two to three months, PEAK-20 initiation is on track for year-end 2026, and a PRISM-1 interim analysis in pancreatic cancer lands in Q4 2026.
Key figures
- Eps
- -1
- Revenue
- 9000000
- Guidance
- Full year 2026 GAAP revenue of $70-75 million; cash runway into 2029
- Cash Position
- 694000000
- Q3 2025 revenue
- 26000000
- First line corr pct
- 50
- Q3 2026 gna expense
- 23000000
- Q3 2026 rnd expense
- 117000000
- October equity proceeds
- 288000000
- Late line median os months
- 35
- Shares outstanding millions
- 127.4
- Second line median pfs months
- 14.5
- First line 12mo landmark pfs pct
- 69
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.